TCRX · TScan Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current operating plan, existing cash and cash equivalents are not expected to be sufficient to fund the Company's obligations for twelve months after the date these condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company is evaluating strategies to obtain the required additional funding for future operations. These strategies may include, but are not limited to, entering into collaboration agreements, offerings of the Company's equity securities, the incurrence of debt, or reductions in operating expenditures. However, there can be no assurance that the Company will be able to obtain additional liquidity when needed, on acceptable terms, or at all. Therefore, substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $7.11M | $10.33M | $2.82M | $21.05M | $13.54M | $10.14M | $1.09M | |
| $97.03M | $114.15M | $107.35M | $88.15M | $59.82M | $44.95M | $20.58M | |
| $30.62M | $31.99M | $30.29M | $26.35M | $20.35M | $13.83M | $6.74M | |
| — | $2.9M | $4.1M | $5.4M | $5.1M | $3.3M | $1.2M | |
| $127.65M | $146.14M | $137.64M | $114.51M | $80.17M | $58.78M | $27.32M | |
| -$120.54M | -$135.81M | -$134.82M | -$93.46M | -$66.64M | -$48.64M | -$26.23M | |
| — | -1315.38% | -4787.68% | -444% | -492.32% | -479.65% | -2417.79% | |
| — | -$132.91M | -$130.72M | -$88.06M | -$61.54M | -$45.34M | -$25.03M | |
| $2.79M | $2.77M | $3.65M | $3.76M | $1.18M | — | — | |
| $2.83M | $6.05M | $7.32M | $4.24M | $415K | $16K | — | |
| — | $0 | — | — | — | — | — | |
| -$117.71M | -$129.77M | -$127.5M | -$89.22M | -$66.22M | -$48.63M | -$26.13M | |
| — | -1256.81% | -4527.66% | -423.86% | -489.26% | -479.49% | -2408.02% | |
| -$117.71M | -$129.82M | -$127.45M | -$89.22M | — | — | — | |
| USD/shares | -$0.91 | -$1.00 | -$1.14 | -$1.36 | -$2.75 | -$4.17 | — |
| USD/shares | -$0.91 | -$1.00 | -$1.14 | -$1.36 | -$2.75 | -$4.17 | — |
| shares | — | 129.78M | 111.99M | 65.6M | 24.05M | 11.66M | 916.01K |
| shares | — | 129.78M | 111.99M | 65.6M | 24.05M | 11.66M | 916.01K |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 275 similar-size Biotechnology companies (of 508 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $10,325,000 | $2,816,000 | $21,049,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2024 | FY2023 |
|---|---|---|
| Reportable Segment | -$134,821,000 | -$93,458,000 |
Operating Margin by Segment (%)
| Component | FY2024 | FY2023 |
|---|---|---|
| Reportable Segment | -4787.7% | -444% |